百济神州的新时代

医药魔方
29 Jun

继首季度盈利之后,近日举办的投资者研发日活动让百济神州又一次站在聚光灯下。全新的管线布局再次验证,百济神州的研发底蕴足够深厚。在泽布替尼已长成全球大单品之际,血液瘤领域的下一次胜利也在酝酿之中,索托克拉已经申报上市,实体瘤领域孵化的一系列待爆潜力分子有望在今年斩获多个概念验证(POC)里程碑。透过管线布局释放的一个更深层信号是,百济神州正在向全球肿瘤药巨头迈进,它在用MNC的体系与打法持续创新输出...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10